Glucagon‐Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Among Type 2 Diabetes Patients: Replication and Reliability Assessment Across a Research Network

Documenti analoghi

• Comparative Safety of Glucagon‐Like Peptide 1 Receptor Agonists ( GLP ‐1‐ RAs ) in Type 2 Diabetes and Chronic Weight Management: A Real‐World Data Study
  di: Sarah Ruth Hurwitz, et al.
  Pubblicazione: (2025)
• The Risk of Hypothyroidism With the Use of GLP ‐1 Receptor Agonists in Saudi Arabia
  di: Almaha Alfakhri, et al.
  Pubblicazione: (2026)
• Glucagon‐like Peptide‐1 Receptor Agonists in Asthma Exacerbations: An Application of High‐Dimensional Iterative Causal Forest to Identify Subgroups
  di: Tiansheng Wang, et al.
  Pubblicazione: (2025)
• Disparity in Guideline‐Based Antidiabetic Drugs Prescribing for Type 2 Diabetes Patients in Primary Healthcare Facilities Across China, 2017–2019
  di: Mengyuan Fu, et al.
  Pubblicazione: (2024)
• Incidence of Diabetic Ketoacidosis in Dapagliflozin‐Treated Japanese Patients With Type 1 Diabetes Mellitus: An Observational Cohort Database Study
  di: Reiko Tamura, et al.
  Pubblicazione: (2025)